In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency
To the Editor: Genome editing using a variety of different nucleases holds great potential to knock out or repair disease-causing genes. An ideal nuclease delivery vehicle is short-lived, does not integrate into the genome and can enter target cells efficiently. These requirements have not yet been achieved simultaneously by any nuclease delivery vector. We and others have used modified mRNA, which is nonintegrating and provides a transient pulse of protein expression, as an alternative to traditional viral vectors [1] [2] [3] [4] [5] . This approach allowed us to deliver therapeutic proteins in mouse models of surfactant protein B (SP-B) deficiency 3 and experimental asthma 4 . Here we apply nuclease-encoding, chemically modified (nec) mRNA to deliver site-specific nucleases in a well-established transgenic mouse model of SP-B deficiency 6 , in which SP-B cDNA is under the control of a tetracycline-inducible promoter 7 . Administration of doxycycline drives SP-B expression at levels similar to those in wild-type mice (Supplementary Fig. 1 ), whereas cessation of doxycycline leads to phenotypic changes similar to those of the human disease, including thickened alveolar walls, heavy cellular infiltration, increased macrophages and neutrophils, interstitial edema, augmented cytokines in the lavage, a decline in lung function and fatal respiratory distress leading to death within days 8, 9 . We inserted a constitutive CAG promoter Anti-3xFLAG flow cytometry shows protein expression in total lung cells and ATII cells. The light blue box presents data from the experimental setup of the dark blue box but without NPs. Boxes, medians ± interquartile ranges; whiskers, minimum and maximum; *P < 0.05 versus unmodified; **P < 0.01 and ***P < 0.001 versus no NPs. y, pseudouridine. (g) Immunostaining for 3xFLAG in lung sections from mice described in f. Scale bar, 50 µm. Arrows indicate 3xFLAG expression.
c o r r e s p o n d e n c e npg delivery, NP-complexation significantly (P < 0.001) increased mRNA expression levels ( Supplementary Fig. 5 ). 3xFLAG protein expression was most robust for the group with mRNA modified with 25% 2-thiouridine (s2U (0.25) ) and 25% 5-methylcytidine (m5C (0.25) ) incorporation and complexed with NP (Figs. 1f,g and Supplementary Fig. 6 ), and no immune activation was observed after i.t. delivery (Supplementary Fig. 7 ). Therefore, subsequent in vivo studies used i.t. delivery of this candidate, called "Z3 necmRNA-NP." Supplementary Fig. 4 ). Comparison with a Z3-encoding AAV serotype 6 vector (AAV6) ("Z3 AAV6") shows the relatively transient expression of Z3 mRNA (Fig. 1e) , limiting the time during which off-target cleavage activity could occur. To optimize expression in the mouse lung, we administered a panel of 3xFLAG-tagged Z3 mRNAs with various modification schemes 2, 5, 10 , with or without complexation to biocompatible, biodegradable nanoparticles (NPs) made of chitosan-coated poly (lactic-co-glycolic) acid 11, 12 . Following intratracheal (i.t.) immediately upstream of the SP-B cDNA to allow doxycycline-independent expression and prolonged life in treated mice.
First, we customized a panel of zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) targeting the transgenic SP-B cassette ( Fig. 1a and Supplementary Fig. 2 ). We chose TALEN no. 1 (T-1) and ZFN no. 3 (Z3) owing to their high activity and proximity to the desired site of promoter integration (Fig. 1a,b) and compared delivery by plasmid DNA and mRNA. mRNA delivery resulted in more frequent induction of double-strand breaks (DSBs) (Fig. 1c and Supplementary Fig. 3 ; P < 0.05) and homology-directed repair (HDR) (Fig. 1d , P < 0.05). As Z3 mRNA was more efficient than T-1 mRNA in both cases, Z3 was chosen for further experimentation (amino acid sequences found in C o R R E S P o N D E N C E npg superior and effective delivery vehicle ( Fig. 2h and Supplementary Figs. 18-20) .
In summary, we have shown that delivery of Z3 nec-mRNA complexed to chitosancoated NPs and AAV6 donor DNA results in successful site-specific genome editing in vivo. To our knowledge no previous study has demonstrated life-prolonging gene correction in the lung. Our study has certain limitations, including the need for co-transfection of an AAV-DNA donor template in conjunction with nec-mRNA, the short duration of the cure in vivo, probably owing to the natural turnover of the transfected lung cell populations, and the use of a transgenic mouse model in which an artificial cassette is targeted rather than a humanized model. Given the transient nature of nec-mRNA action, this therapeutic modality is best suited to the numerous scenarios in which shortterm genome editing can effect long-term clinical benefit.
METHODS
Methods and any associated references are available in the online version of the paper. Next, we designed a complementary donor template to insert a constitutive CAG promoter at the Z3 nec-mRNA-NP cut site, upstream of the transgenic SP-B cDNA ( Fig. 2g and Supplementary Sequences). Successful site-specific HDR would allow mice to survive and produce SP-B in the absence of doxycycline. As the donor template must be delivered in excess to ensure that it is favored over the homologous chromosome during HDR, we used AAV6, a vector known to transduce lung cells with high efficiency 4 . Ex vivo delivery of the AAV6 donor with Z3 nec-mRNA-NP resulted in successful HDR in primary fibroblasts (Supplementary Fig. 8 ). The AAV6 donor and Z3 nec-mRNA-NP (or a Z3 AAV-control) were then delivered in a time-shifted manner to the lungs of transgenic SP-B mice and doxycycline was withdrawn (Fig. 2a) . Notably, mice in these groups lived significantly longer compared with matched control groups ( Fig. 2a , P < 0.001), while maintaining SP-B expression levels similar to those of mice receiving doxycycline, for as long as 20 days after cessation of doxycycline (Fig. 2b,c and Supplementary Figs. 9 and 10) . Combining gene correction with AAV6 donor and Z3 nec-mRNA-NP (or Z3 AAV) prevented the decline in lung function ( Fig. 2d and Supplementary Fig. 11 ), severe hemorrhagic infiltrations and large-scale edema (Supplementary Figs.  12-14) , and neutrophilia ( Supplementary  Fig. 15 ), all of which are observed in the lungs of negative controls. A nonsignificant increase of interleukin (IL)-12 was observed in Z3 nec-mRNA-NP versus PBS-treated mice ( Supplementary Fig. 16) ; however, no interferon (IFN)-a elevation was detected (data not shown). Biodistribution analyses revealed that AAV persistence was restricted to the lung, with no detectable expression in heart, liver, kidney or spleen (data not shown). DSB and HDR rates (the latter determined by in-out PCR; Fig. 2g) were consistent with successful gene manipulation (Fig. 2e,f) , which was also determined by target-site sequencing (Supplementary Fig. 17 ). If achieved in humans, HDR rates of ~9% (Fig. 2g) would likely be sufficient to avoid severe disease progression (Supplementary Discussion). These results also confirmed that nuclease expression was longer-lived if administered by AAV, making Z3 nec-mRNA-NP a
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ONliNE METHODS
Site-specific nucleases. TALENs and ZFNs targeting the transgenic SP-B cassette were assembled using an archive of zinc-finger proteins, as previously described 13 . The full amino acid sequences of the Z3 pair are shown in Supplementary  Figure 3 . The ZFN expression vector was assembled as previously described 14 . The respective plasmid constructs were kindly provided by Sangamo BioSciences (www.sangamo.com).
Targeting vectors. The targeting vector carrying the CAG promoter was assembled from synthetic oligonucleotides (www.lifetechnologies.com) and PCR products, and was verified by sequencing. The full DNA sequence of the donor vector is depicted in Supplementary Figure 5 . The NheI restriction fragment length polymorphism (RFLP) donor plasmid was constructed by removing the CAG promoter from the targeting vector by NheI digestion, leaving a single NheI restriction site, which was used in the RFLP assays.
Cell culture and transfection. For the T7 and HDR assays 1 × 10 6 fibroblasts in 6-well plates were transfected as indicated in the respective figure legends using the Neon electroporation system (www.lifetechnologies.com) with 100 ml tips. The electroporation settings were 1,650 V, 20 ms, 1 pulse. A549 cells (human ATII cells, the cell type responsible for SP-B expression in the lungs) and MLE12 cells (murine ATII cells) were maintained at 37 °C under 5% CO 2 and grown in minimal essential medium (www.lifetechnologies.com), supplemented with 10% FCS, 1% penicillin-streptomycin. One day before transfection, 50,000 or 80,000 cells/well/500 ml were plated in 24-well plates. The cells (70-90% confluent) were transfected with 5 mg (T7 assays, fragment analyses and RFLP) or 1 mg Z3 pair nec-mRNA (time-course experiment) using Neon electroporation (www.lifetechnologies.com) with a transfection mix volume of 100 ml according to manufacturer's instructions or transduced with a multiplicity of infection (MOI) of 1 × 10 6 v.g. of each Z3 AAV6. For transfection experiments demonstrated in Figure 1d , we equilibrated the DNA amounts by adding inert (empty vector) DNA to a total of 9 mg each. For transduction, the cells were washed once with PBS and cultured in OptiMEM; 6 h after transduction 10% FCS was supplied. After 24 h the medium was removed, the cells washed once with PBS, and fresh culture medium added. Primary fibroblasts from transgenic SP-B mice were obtained by removing the dorsal skin, followed by separation of epidermis from the dermis using dispase. After further digestion of the dermis using collagenase, the suspension was passaged through a 70-µm strainer. After the wash and centrifugation steps, the cell pellet was resuspended in fibroblast culture medium (DMEM/ Ham's F-12 medium with l-glutamine, 10% MSC grade fetal calf serum, 1× MEM nonessential amino acids, 1× sodium pyruvate, 1% penicillin/streptomycin, 0.1 mM 2-mercaptoethanol). For the time course experiments: 1, 2, 3, 4, 5 and 14 days after transfection the A549 cells were harvested, permeabilized using BD Cytofix/Cytoperm plus (www.bd.com), stained with APC anti-DYKDDDK clone L5 (www.biolegend.com) antibody and analyzed on an LSR-I flow cytometer (http://www.bd.com/); data were analyzed with BD FACSDiva software (http:// www.bd.com/).
Generation of nec-mRNA. To generate templates for in vitro transcription the 3xFLAG-tagged T-1 and Z3 were cut out of their original vectors and subcloned into a PolyA-120 containing pVAX1 (www.lifetechnologies.com). The plasmids were linearized with XbaI and transcribed in vitro using the MEGAscript T7 Transcription kit (www.lifetechnologies.com), incorporating 25% 2-thio-UTP and 25% 5-methyl-CTP or 100% PseudoUTP and 100% 5-methyl-CTP (all from www.trilinkbiotech.com). The anti reverse CAP analog (ARCA)-capped synthesized nec-mRNAs were purified using the MEGAclear kit (www.lifetechnologies. com) and analyzed for size on agarose gels and for purity and concentration on a NanoPhotometer (http://www.implen.com).
T7 nuclease assay. Genomic DNA was extracted from fibroblasts using the DNeasy Blood & Tissue Kit (www.qiagen.com). A 50-µl PCR reaction was set up using 100 ng of gDNA derived from fibroblasts previously transfected with 5 µg T-1 or Z3 pair, 0.5 µM primers (for T-1: fwd, "P3" GTAGGCGTGTACGGTGGGAG; rev, "P1" CAGCAGAGGGTAGGAAGCAGC; for Z3: fwd, TGTACGGTGGGAGGCCTAT; rev, CCTGGCAGGTGATGTGG), and AmpliTaq Gold 360 Mastermix (www. lifetechnologies.com). Another PCR reaction was performed using the same primer sets, but with gDNA from untransfected cells. The PCR products were run on agarose gels to verify size and sufficient amplification, pooled, purified by ethanol precipitation, dissolved in 20 ml water and the DNA concentration was measured on a NanoPhotometer. 2 ml NEBuffer 2 (www.neb.com), 2 mg purified PCR product and water were brought to a total volume of 19 ml. The DNA was hybridized in a thermocycler according to the following protocol: 95 °C for 5 min, 95-85 °C at -2 °C/s, 85-25 °C at -0.1 °C/s, hold at 4 °C. 1 ml (10 U) of T7E1 (www. neb.com, M0302L) was added and incubated at 37 °C for 15 min. The reaction was stopped by adding 2 ml of 0.25 M EDTA. The reaction was again purified by ethanol precipitation and dissolved in 15 ml water. The nuclease-specific cleavage products were determined on agarose gels. The band intensities were quantified using ImageJ (http://rsb.info.nih.gov/ij/).
For measuring off-target effects, A549 cells were transfected 5 mg mRNA or transduced with 1 × 10 5 v.g. AAV6-Z3. PCR and T7 was performed as described above (primers: off-target 1: fwd, GCAAGTTTGGCGTCGCTCCA; rev, AGAGGAAGGCGCGGCAGG; off-target 2: fwd, TTCTTGCTCCAGTGACTCTCTTA; rev, AGCCTAGTAAAGACAACACTAGTG; off-target 3: fwd, CAACGTGACCTGCGAGCG; rev, GTGCACGCTCCACTTCTCG; off-target 4: fwd, CTGGAGATGCATCCTTGTCTGT; rev, GAGGGTGAAGACTTTTGGAGCT; off-target 5: fwd, CAGCACCAGATGTTCCCTGTTA; rev, TGGAAAGCAATAGTTCTAGGATGA; off-target 6: fwd, GAGGCTGTGTCACTAGCAGGA; rev, CAAAGTGGTACCTTGGCAAGAG; off-target 7: fwd, AGAAAGCCAGCTGAGTACCA; rev, TGTTGGCTTGTTTGGACTCATG; off-target 8: fwd, TGACTACAATCATGCTTCTTGGTT; rev, TGTAGGCCTTCAGTGATCTAGG; off-target 9: fwd, AAGGACTTCATCTTTGCTGGAT; rev, GAATCAACAGCCTGGCAGC; off-target 10: fwd, ACATTTTCTGGAGTGTAGTGTG; rev, GCTCTTTCGGTAACACAGTTCTT).
HDR/RFLP assay. Genomic DNA was extracted from fibroblasts or lung tissue using the DNeasy Blood & Tissue Kit (www.qiagen.com). T-1 or Z3 target loci were amplified by PCR (40 cycles, 58 °C annealing and 30 s elongation at 72 °C; 5 min at 72 °C to assure completion of amplicons) using 0.5 mM of primers T-1fwd (GTAGGCGTGTACGGTGGGAG) and T-1rev (CAGCAGAGGGTAGGAAGCAGC), as well as P1 and P3 (see above) with AmpliTaq Gold 360 Mastermix. In addition, in-out PCR reactions were performed using primers P1 and P2 (AGGCACTGGGCAGGTAAGTA) (see Supplementary Fig. 20) .
Flow cytometry. Harvested lungs were digested at 37 °C for 1 h on a rotating shaker in 1 mg/ml collagenase type I (www.lifetechnologies.com), 1% (500 U) DNase (www.epibio.com) solution. Digested lung was passed through a 40-mm nylon cell strainer and erythrocytes were lysed using ACK Lysing Buffer (www. lifetechnologies.com). PE anti-CD45 clone 30-F11, PE anti-CD31 clone C13.3, APC anti-mouse Ly-6A (Sca-1) clone D7 (www.biolegend.com), FITC anti-FLAG M2 and anti-clara cell secretory protein (www.sigmaaldrich.com) were used to stain lung cells. After staining for extracellular markers, cells were fixed and permeabilized using BD Cytofix/Cytoperm plus (www.bd.com), then stained with intracellular antibodies. Flow cytometer analyses were performed on a LSR-I flow cytometer (www.bd.com) and data were analyzed with BD FACSDiva software (www.bd.com).
ATII and Clara cells sorting was performed with a FACSAria (www.bd.com).
Nanoparticles. Chitosan (83% deacetylated (Protasan UP CL 113, www. novamatrix.biz)) coated PLGA (poly-d,l-lactide-co-glycolide 75:25 (Resomer RG 752H, www.evonik.de) nanoparticles (short: NPs) were prepared by using emulsion-diffusion-evaporation 15 with minor changes. In brief, 100 mg PLGA was dissolved in ethyl acetate and added dropwise to an aqueous 2.5% PVA solution (polyvinyl alcohol, Mowiol 4-88, www.kuraray.eu) containing 15 mg Chitosan. This emulsion was stirred (1.5 h at room temperature) and followed by homogenization at 17,000 r.p.m. for 10 min using a Polytron PT 2500E (www.kinematica.ch). These positively charged NPs were sterile filtered and characterized by Malvern ZetasizerNano ZSP (hydrodynamic diameter: 157.3 ± 0.87 nm, PDI 0.11, zeta potential +30.8 ± 0.115 mV). After particle formation they were loaded with mRNA by mixing (weight ratio, 25:1).
AAV vector production. AAV serotype 6 vectors from the Z3 pair and the donor sequence were produced and purchased from Virovek (www.virovek.com).
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